Dosing has begun in a Phase 1 trial of ZI-MA4-1, the first MAGE-A4-targeting TCR-NK cell therapy for solid tumours, with initial data expected from mid-2026. The off-the-shelf therapy is being evaluated at two UK sites.
Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.
Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07648940 |
Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients |
COMPLETED | PHASE1 |
| NCT07075939 |
Centralization and Oncologic Outcomes in Ovarian Cancer |
RECRUITING | |
| NCT06997029 |
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT04862325 |
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS |
COMPLETED | NA |
| NCT03737643 |
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients |
ACTIVE_NOT_RECRUITING | PHASE3 |
